Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of WINDTREE THERAPEUTICS INC /DE/
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000946486.
Disclosed value leader
James Huang
Comparable rows
1/14
Latest evidence
31 Dec 2024
- Public ticker
- WINT on OTC
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 14
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Dec 2024
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000946486
- Issuer location
- Warrington, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of WINDTREE THERAPEUTICS INC /DE/ (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
James Huang
Comparable rows
1/14
Latest evidence
31 Dec 2024
13D/G
3/4/5
Lead comparable stake: 2.6%
13 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 14 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 2.6%.
1 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 1
ARMISTICE CAPITAL, LLC
2.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
2.6%
|
$28,855
288,552 shares
|
$0 | 31 Dec 2024 |
| Center Laboratories, Inc. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$2,527,492
2,782,352 shares
mixed-class rows
|
— | 20 May 2020 |
| Bioengine Capital Inc. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
—
304,176 shares
mixed-class rows
|
— | 20 May 2020 |
| James Huang |
3/4/5
Director
|
—
mixed-class rows
|
$3,819,976
5,970,058 shares
mixed-class rows
|
— | 22 Feb 2023 |
| John P. Hamill |
3/4/5
SVP & CFO
|
—
class O/S missing
|
$74,249
72,800 shares
|
— | 26 Jul 2022 |
| Craig Fraser |
3/4/5
President and CEO, Director
|
—
mixed-class rows
|
$59,032
12,669 shares
mixed-class rows
|
— | 08 Oct 2024 |
| Steven Simonson |
3/4/5
SVP, Chief Medical Officer
|
—
mixed-class rows
|
$17,793
43,933 shares
mixed-class rows
|
— | 22 Jul 2024 |
| Eric Curtis |
3/4/5
SVP & COO
|
—
mixed-class rows
|
$16,237
37,920 shares
mixed-class rows
|
— | 23 Aug 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 01 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to WINDTREE THERAPEUTICS INC /DE/. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
James Huang
Net 12M change
$0
Latest report
03 Aug 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| James Huang | Director | $3,819,976 | Mixed | 22 Feb 2023 | ||
| Center Laboratories, Inc. | 10%+ Owner | $2,527,492 | Mixed | 20 May 2020 | ||
| John P. Hamill | Svp & Cfo | $74,249 | Mixed | 26 Jul 2022 | ||
| Craig Fraser | President and CEO, Director | $59,032 | Mixed | 08 Oct 2024 | ||
| Steven Simonson | SVP, Chief Medical Officer | $17,793 | Mixed | 22 Jul 2024 | ||
| Eric Curtis | Svp & Coo | $16,237 | Mixed | 23 Aug 2023 | ||
| Jamie McAndrew | VP, Controller, & CAO | $10,438 | Mixed | 24 Aug 2023 | ||
| Mark Strobeck | Director | $2,346 | Mixed | 23 Aug 2023 | ||
| Daniel E. Geffken | Director | $2,218 | Mixed | 23 Aug 2023 | ||
| Robert A. Scott | Director | $2,175 | Mixed | 23 Aug 2023 | ||
| Leslie J. Williams | Director | $2,175 | Mixed | 23 Aug 2023 | ||
| Diane Carman Esq. | SVP & General Counsel | $1,251 | Mixed | 28 Feb 2023 | ||
| Andrew Albert Kucharchuk | Director | Mixed | 03 Aug 2025 | |||
| Jed Latkin | Director | Mixed | 13 Aug 2024 | |||
| Saundra L. Pelletier | Director | Mixed | 13 Aug 2024 | |||
| Leanne Kelly | Director | Mixed | 08 Jan 2025 | |||
| John A. Tattory | Interim CFO | Mixed | 27 Jan 2023 | |||
| Bioengine Capital Inc. | 10%+ Owner | Mixed | 20 May 2020 |
Recent insider transactions for WINDTREE THERAPEUTICS INC /DE/
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.